TPST

Tempest Therapeutics, Inc.
CAPPED RATING

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics, Inc. (TPST) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.3
EV / EBITDA -0.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -66.2%
Price Return 12M -95.6%
Catalyst Signal 0.00
Market Cap $7.6M
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.8) C- (1.9) F (0.6) C+ (2.6) C- (1.9)
2026-11-08 C+ (2.5) C- (1.9) C- (1.9) F (0.7) C+ (2.6) C- (1.9)
2026-11-01 C+ (2.5) C- (1.9) C- (1.9) D- (1.0) C+ (2.7) C- (2.0)
2026-10-25 C+ (2.5) C- (1.9) C- (1.9) D- (1.0) C+ (2.6) C- (2.0)
2026-10-18 C+ (2.5) D+ (1.8) C- (1.9) D (1.2) C+ (2.6) C- (2.0)
Page 1 of 3